Daewoong Pharmaceutical Co Ltd (Daewoong Pharmaceutical), a subsidiary of Daewoong Co Ltd, focuses on the research, development, manufacturing and commercialization of pharmaceuticals. The company offers a broad portfolio of biologics, small‑molecule chemicals, over-the-counter (OTC) products, pipeline candidates, and diagnostic/medical devices with therapies across aesthetics, endocrinology, nephrology, gastroenterology, cardiometabolic disease, and wound care.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Daewoong Pharmaceutical is focused on transforming patients' lives through innovative therapeutics, high-quality biopharmaceuticals, and next-generation platform technologies. The company is advancing beyond Korea to lead global healthcare by developing new drugs, biopharmaceuticals, and platform technologies. Daewoong Pharmaceutical's R&D initiatives are driven by an innovative pipeline and differentiated technological capabilities, generating outcomes recognized across the global market. The R&D units of Daewoong Pharmaceutical include the Daewoong Magok C&D Center in Seoul, Korea, which focuses on synthetic biologics and formulation platform clusters; the Daewoong Bio Center in Yongin, Gyeonggi-do, Korea, which specializes in recombinant proteins and cell and gene technologies; the UI Bio Technology & Analytics Research Centre in Depok, Indonesia, which works on cell therapy, organoids, and gene editing; the IPB Primate Research Center in Bogor, Indonesia, which conducts primate research and training of veterinary professionals; the Daewoong Life Science Research Institute in Yongin, Gyeonggi-do, Korea, which focuses on innovative new drugs and platform technologies; the ITB DDS Research Institute in Bandung, Indonesia, which is involved in the research and development of platform technologies; and the UI Biotechnology Research Center in Depok, Indonesia, which analyzes proteins and biological samples. The company is actively expanding its R&D pipeline across various therapeutic areas, including autoimmune diseases, metabolic disorders, fibrosis, and oncology. In FY2025, the company spent KRW180,314.7 million on its R&D activities, which as a percentage of revenue stood at 11.5%.